Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|December 23, 1998
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screeningE Boven, H M Pinedo, A H van Hattum, et al.
Breast (Edinburgh, Scotland)|January 12, 2013
Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA studyM E Hamaker, C Seynaeve, J W R Nortier, et al.
British Journal of Cancer|January 1, 1997
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancerR de Wit, R Sylvester, C Tsitsa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsH R Hendriks, P E Pizao, D P Berger, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|September 18, 2009
Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasisI S van Houdt, B J R Sluijter, P A M van Leeuwen, et al.
Breast Cancer Research and Treatment|May 24, 2023
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancerM K Bos, S W Lam, G Motta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 1997
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancerA H Honkoop, E van der Wall, N Feller, et al.
British Journal of Cancer|July 3, 2008
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancerA A M van der Veldt, E Boven, H H Helgason, et al.
The Oncologist|May 25, 1999
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancerA H Honkoop, S A Luykx-de Bakker, K Hoekman, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2014
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trialS W Lam, S M de Groot, A H Honkoop, et al.
Pageof 13